Pfizer Inc./Hospira, Inc., In the Matter of

Last Updated:
In the Matter of Pfizer Inc., a corporation; and Hospira, Inc., a corporation
FTC Matter/File Number:

151 0074

Docket Number:


Enforcement Type:

Part 2 Consents

Case Summary

Pfizer Inc. agreed to sell the rights and assets related to four pharmaceutical products in order to settle FTC charges that its proposed $16 billion acquisition of Hospira, Inc. would likely be anticompetitive. Pfizer is one of the world’s largest drug companies and principally competes with Hospira in markets for certain sterile injectable pharmaceutical products. The order requires Pfizer to supply Alvogen with the clindamycin phosphate injection product for three years while Pfizer transfers the manufacturing technology to Alvogen or its designee. Pfizer also is required to provide transitional services to Alvogen to assist with establishing manufacturing capabilities and securing FDA approvals to market all of the divested products.